text:
Trinity Biotech Plc (NASDAQ:TRIB)
Q3 2012 Earnings Conference Call
October 18, 2012 11:00 a.m. ET
Joe Diaz – Lytham Partners
Ronan O'Caoimh – CEO
Kevin Tansley – CFO
Rory Nealon – COO
Chris Lewis – ROTH Capital Partners
Laura McGuigan – B Riley
Ross Taylor – Somerset Capital
Dave Cohen – Midwood Capital
Walter Schenker – MAZ Partners
Jeffrey Warshauer – Sidoti
Paul Nouri – Noble Equity Funds
Hello, and welcome to the Trinity Biotech Third Quarter 2012 Financial Results Conference Call. (Operator Instructions)
I would now like to turn the conference over to Joe Diaz of Lytham Partners. Please go ahead.
Joe Diaz
Thank you, Amy, and good morning to all of you joining us to review the financial results of Trinity Biotech for the third quarter ended September 30, 2012.
As the operator indicated, my name is Joe Diaz. I'm with Lytham Partners. We're the financial relations consulting firm for Trinity Biotech.
With us on the call representing the company today are Ronan O'Caoimh, Chief Executive Officer; Rory Nealon, Chief Operating Officer; Kevin Tansley, Chief Financial Officer; and Jim Walsh, Chief Scientific Officer and Business Development Director.
At the conclusion of today's prepared remarks, we'll open the call for a question-and-answer session. If anyone participating on today's call does not have a full text copy of the press release, you can retrieve it off the company's website at trinitybiotech.com or numerous financial sites on the Internet.
Before we begin with prepared remarks, we submit for the record the following statement. Statements made by the management team of Trinity Biotech during the course of this conference call that are not historical facts are considered to be forward-looking statements subject to risks and uncertainties.
The Private Securities Litigation Reform Act of 1995 provides a Safe Harbor for such forward-looking statements. The words believe, expect, anticipate, estimate, will, and other similar statements of expectation identify forward-looking statements. The forward-looking statements contained herein are subject to certain risks, uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking statements included herein.
Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development, commercialization and technological difficulties and other risks detailed in the company's periodic reports filed with the Securities and Exchange Commission.
Participants on this call are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
With that, let me turn the call over to Kevin Tansley, Chief Financial Officer of Trinity Biotech. He will be followed by Rory Nealon with a review on the Premier project, and he will be followed then by Mr. Ronan O'Caoimh, the Chief Executive Officer with his review of the quarter. Kevin?
Kevin Tansley
Thanks, Joe. I am going to give you an update on the financial results for quarter three 2012, the details of which are contained in the press release as we issued earlier today.
Firstly, I'll briefly discuss our revenue performance. As you'll have seen from the press release, our total revenue this quarter were $20.9 million. This compares to $19.8 million in quarter three of last year, and represents growth of 5.2%. However, excluding the impact of foreign exchange movements – mainly the weaker euro – the overall increase would have been approximately 8%.
Point-of-care revenues increased by 20.6% from $3.9 million to $4.8 million. Meanwhile clinical laboratory revenues increased from $15.9 million to $16.1 million, an increase of 1.4%. However, excluding the impact of currency movements and Fitzgerald revenues, which were down slightly in the quarter, the increase in clinical lab revenues would have been 6%. Ronan will provide you with more details on revenue later in the call.
Now, moving on to gross margin. This quarter's gross margin was 51%, which is slightly down on the 51.7% we reported in quarter three last year. Lower gross margins attributable to higher instrument placements – predominantly sales of our new Premier instrument, which increased to 54 units this quarter. I've mentioned before that we can expect gross margins to be a little lower than some quarters due to placements such as these, as instrument sales typically have lower margins.
Moving on to indirect expenses, our R&D expenses of $800,000 this quarter were at similar levels to those recorded in the equivalent quarter last year. Meanwhile, our SG&A expenses have decreased slightly to $5.1 million. This has been due to continuous cost management, but it's also impacted by exchange rate movements.
As I've mentioned on previous calls, we effectively have a natural hedge from an FX perspective. In other words, our foreign-currency-denominated revenues and expenses are broadly equal. Whilst our revenues have been impacted by a weaker euro, so our SG&A expenses are down also for the same reason.
Operating profits for the quarter increased from $4.1 million to $4.35 million. And this brought the operating margin up to 20.9%. This is the highest operating margin that the company has ever achieved. As I mentioned in the press release, this is the key metric for us, as it indicates the extent to which future revenue growth will be converted into enhanced profits going forward. This is now the sixth quarter in a row with an operating margin in excess of 20%.
Moving on next to our net financial income, this quarter we earned $597,000, which is slightly up in the equivalent period last year, thus reflecting our strong cash balances. Meanwhile, our tax charge for the quarter was $460,000, which represents an effective tax rate of just under 9.3%, bringing the average for the year to 11%. This is obviously a lower rate than many companies similar to ours, and demonstrates the benefits we are deriving from lower corporation tax rates in Ireland.
From an overall profitability point of view, we've had a very good quarter. Profit after tax has now grown to close to $4.5 million, and this compares to $3.9 million last year, or an increase of 13%. It's not that long ago since $4.5 million would have been close to the company's profit for the year as a whole, rather than in one quarter. And this shows the rapid increase in profits that we have achieved in a few short years.
Meanwhile, we have also grown EPS for the quarter to 20.7 cents per ADR or an increase of 12% and in diluted EPS terms, we're seeing this grow from 17.7 cents to 19.8 cents per ADR over the same period, again an increase of 12%.
Finally, earnings before interest, tax, depreciation, amortization and share option expense for the quarter amounted to $5.6 million. I'd like to reiterate it's been a very strong quarter from a profits perspective. I'll now move on to talk about the significant balance sheet movements since the end of June 2012.
Property, plant and equipment have increased by $400,000. And this is made up of additions of $800,000 as offset by a depreciation charge of $400,000. During the same period, our intangible assets increased by $3.4 million, and this was due to additions and other movements of $3.8 million, which is higher than in previous quarters due to increased expenditure in developing our new cardiac test at our Fiomi subsidiary in Sweden. So the additions have been partly offset by an amortization charge of almost $400,000.
Moving on to inventory, you'll see that this has increased by about $600,000 this quarter. It was well within the norm of fluctuations for inventory quarter-on-quarter, and the principal reason is the increase in Premier-related inventory, which as well as safety stock of finished instruments, also now include spare parts we are required too hold to support the increasing number of instruments in the field.
Meanwhile, trade and other receivables have increased by $600,000 to $15.6 million. Our overall AR book remains in very good shape at 54 days.
Finally, in relation to working capital, our trade and other payables have remained static at $11.8 million.
Before I hand it over to Rory I will discuss our cash flows for the quarter. Cash from operations increased during the period to $4.9 million reflective of the improved operating margins and profitability that I mentioned earlier. However, we are seeing a reduction in free cash flows as was the last quarter. This was due to the additional expenditure on the development of our new point-of-care cardiac product following the acquisition of Fiomi earlier this year.
Notwithstanding this, we still achieved free cash flow for the quarter of just under $2 million, which is very much in line with our revised expectation. I would like to point that, but notwithstanding the fact that we are undertaking a significant R&D program, we're able to fund this cash from operations, while at the same time generating a surplus which can be used for share buyback or annual dividend.
Finally, we spent closed to $1.1 million purchasing additional 85,000 shares during the quarter. On an overall basis, we had a very good quarter with the key points being achievements of profits of $4.5 million for a single quarter; EPS growth of 12% and so far for the first nine months of this year we've achieved earnings of just over $0.60 per share. So I'm confident that we will exceed our target of $0.80 for the year as a whole.
I'll now hand over to Rory, who'll update you on the Premier project.
Rory Nealon
Thanks, Kevin. I'll just give you a very brief update on the Premier project after which Ronan will give you an overview of the quarter. Some of you have heard me say on this call before that there are various phases to our Premier project.
Phase I look to develop the Boronate Affinity instrument, which as you know was FDA-approved in December 2011 and as noted in our press release we're on target – well on target to sell 200 of these instruments in 2012.
Phase II of the project is to develop an ion exchange version of the same instrument. Now you've heard me tell you before the benefits of boronate affinity over ion exchange. So I don't propose to go through them again. However, ion exchange does have one particular advantage in certain unique markets. Specifically, ion exchange will enable the physician to identify the presence of hemoglobin variance and normally when one is measuring A1c, it is not a requirement but in certain jurisdictions for Thalassemia is endemic.
It is accepted practice to look for such variance in particular A2 and F while measuring A1c. Southern Europe in particular the Mediterranean countries of Italy, Spain, Portugal and Greece is the main area where Thalassemia is present and as a result we are currently developing an ion exchange version of the Premier to enable Menarini target those particular countries.
As an Italian company you can appreciate there are significant proportion – just less than 50% of the Menarini business – is in these Mediterranean countries and consequently this will result in a major increase in monthly sales of instruments to Menarini once we launch this ion exchange instrument in these markets.
So we've been working on this ion exchange project for over a year now. And as of today we have firstly with the hardware in place which is essentially the same hardware as the boronate affinity instrument with some minor changes. We have the first version of software completed and working on the instruments. And we're currently dialing in the gradient or fine-tuning the chemistry to complete the system. As a result we expect to go to clinical trials in the first half of next year and we expect to launch this new product in Europe with Menarini in quarter three 2013. So from 2013 onwards or Q3, 2013 onwards customers will obviously then be in a position to choose between either the boronate affinity version of the instrument or the ion-exchange version of the instrument.
Back to you, Ronan.
Ronan O'Caoimh
Thank you, Rory. Our sales in the quarter were $20.9 million, up from $19.8 million and it's a quarter three of last year, which has increased to 5.2%. As Kevin has said when the impact of the weakening euro is taken into account, the underlying organic growth is 8%. HIV point-of-care revenues were at $4.8 million, up from $3.9 million, which is an increase of 20%. Within these numbers U.S. HIV revenues were actually down 8% compared with the same quarter last year and this reflects reduced spending by many individual states on their HIV programs. This reduction is being experienced also by our principal competitor in this market in the USA.
The situation in Africa is very different where our revenues have increased 29% compared with the same quarter last year. The exceptional quality of our product which is the only FDA approved HIV product available in Africa is leading to a situation where we are the confirmatory HIV test of choice for the NGOs and the countries in virtually all African countries. The outlook for our African business in coming quarters is very strong.
Clinical Laboratory revenues were $16.1 million, up from $15.9 million in the same quarter last year, which is an increase of 1.4%. However, again as Kevin has stated, if we exclude the impact of the weakening euro and our growth achieved was 5% and 6% if we also exclude the drop in Fitzgerald revenues. Although, again as Kevin has pointed out, although the weaker euro has the impact of reducing our revenues it also reduces our cost by an equal amount. And given that we have a virtual balance between euro revenues and costs those have bottom line and our earnings per share are not impacting us.
Our core infectious disease business performed well particularly in the United States and China. The launch of our new Vitamin D test is attracting a lot of interest and will drive instrument placements. We anticipate that the Vitamin D test will be a real catalyst for growth. We have received FDA approval for the product to be used on the DS2 instrument and have submitted to the FDA for use on the more popular DSX instrument.
When the product is approved on the DSX instrument which, we expect over the next six weeks, we expect then significant success with the Vitamin D product in the U.S. market. And we have developed – we've commenced a development of three new lines of tests for Chagas, West Nile Virus and Dengue, which will run on our DSX instrument. Development of these products will be completed in quarter two of next year and the product should be FDA approved within the year of today.
This project is part of our plan to make available esoteric tests for our customers that differentiate us from our competitors. The Chagas, West Nile Virus and Dengue tests are being developed for sale in the United States and in the case of Chagas in Brazil also and in the case of Dengue in Southeast Asia as well as the United States. We're continuing to work for more products approvals in both China and Brazil, which are two key growth markets for the company.
Moving on to diabetes, the launch of our new Premier instrument continued successfully, and we are pleased to report that we placed 54 instruments this quarter up from 31 instruments in quarter one and 52 instruments in quarter two. A further 67 placements in quarter four would achieve our target of 200 placements for the year 2012, and we are confident of exceeding this number.
Shipments to Menarini in Europe in quarter three were marginally lower than quarter two, but this reflects the fact that Italy closes down completely more or less completely for the month of August and orders on hand for quarter four indicate a significant upturn. As we already have explained in some detail to you a moment ago, Menarini has very significant upside potential as soon as we complete the ion exchange version of the Premier instrument.
The level of placements with Menarini will virtually double in quarter three or quarter four of 2013 when we launch the ion exchange instrument, because again as Rory's pointed out, at the moment our instrument – at the moment our instrument is unsuitable for Southern Italy, Southern Spain and all of Greece and Portugal, which are Menarini's strongest markets.
Meanwhile in the United States placements are improving as opinion leaders are progressively supporting our instrument and as we achieve better engagement from Thermo Fisher. A key market for us will be China and we believe that we would get the instrument approved by the Chinese FDA during the month of January coming i.e., in three months time. We believe that this will immediately be a 100 instrument per year market for us. Remember, we already have 120 of our old instrument placed in China.
Brazil will also be a big market for us and we are getting ever closer to an approval. We now estimate approval in quarter two of 2013. We continue to launch around the world and as examples during the quarter we gained Taiwanese approval and placed five instruments in Taiwan, and also we launched in the South American Andean region and placed four instruments there.
In summary, we are confident of exceeding our goal of 200 instrument placements in 2012. We expect to exceed 300 placements in 2013 and 400 in 2014.
Moving on to our point-of-care development projects at our San Diego facility, we have submitted Giardia and Cryptosporidium to the FDA and expect approval for both in the coming weeks. Clostridium Difficile and Strep pneumonia are in clinical trials will be CE marked before Christmas with FDA approval anticipated four months later.
This means that Giardia, Cryptosporidium, Clostridium Difficile, Legionella Urinary Antigen and Strep pneumonia will all be on sale in Europe by the year end and all available in the U.S. by quarter two of next year.
Now if I may, I'd like to take this opportunity to provide you with a brief update on progress of our cardiac market development program in Uppsala, in Sweden. You'll remember that seven months ago Trinity Biotech announced the acquisition of the Swedish company Fiomi Diagnostics for a consideration of $13 million. Fiomi has developed a high sensitivity, quantitative instrument-based point-of-care immunoassay platform on which we are developing a complete range of high sensitivity cardiac marker assays.
Just to remind you the point-of-care cardiac market is currently estimated to be worth $900 million and is growing at a rate of 14% annually. The main participants in this market are Alere with the Biosite Triage platform, Abbott with the i-STAT platform and Roche with the COBAS handheld platform.
The market is segmented as a 45% United States, 27% Europe, 13% Japan and the rest of the world as 15%. The entire $900 million market is almost completely addressed through two key products namely high sensitivity Troponin I, which is the indicator of acute cardiac issues, and BNP, which is the indicator of heart failure.
I'm really happy to report at this time that for both of these assays the Fiomi platform is consistently displaying significant to superior sensitivity, but more importantly superior precision to the market leading platforms thus leading Trinity to believe that it can take a significant share out of this market when its panel of cardiac assays are released to the European market towards the end of 2013 and to the U.S. market following the U.S. – following U.S. FDA approval in mid to late 2014.
With regard to the planning for the U.S. regulatory process, two pre-IDE meetings have been held with the FDA to-date. We have reviewed very clearly – clearly with the FDA the new clinical guidelines, particularly as they relate to the approval of high sensitivity Troponin I assay.
At this time, the size and scope of the U.S. clinical trials has been determined; moreover, we have engaged with a number of key opinion leaders in both the U.S. and Europe to help identify the appropriate trial sites and to help guide us through the clinical trial process all going well data collection for CE marking of the Troponin assay will commence in April 2013 with U.S. data collection commencing in the July 2013 timeframe.
BNP will follow approximately three months after this. In summary, we are very pleased with the Fiomi team and with the technology and look forward to taking a significant share of the $1 billion point-of-care cardiac market in 2014 and onwards.
Now before I open up for question-and-answer session, I just mention that on the subject of buyback, during the quarter, the company bought back 85,000 shares at an average price of $12.53. On a related note, at the end of the quarter, we held an EGM, which approved the conversion of the company's B shares into A shares or ADRs at a discount of 15%.
At the end of the quarter we entered in agreement to repurchase 100,000 of the newly created ADRs from the former B shareholders at a price of $12.47 or a total consideration of $1.25 million. However, this agreement is only processed in the early days of quarter four. Thus the effective purchases for the quarter were 185,000 shares at a total cost of $2.3 million.
So if I could hand back to the operator now for a question-and-answer session. Thank you.
Question-and-Answer Session
(Operator Instructions) Our first question comes from Matt Dolan at ROTH Capital Partners.
Chris Lewis – ROTH Capital Partners
Hey, guys. This is Chris Lewis on the line for Matt. Thanks for taking the questions.
Ronan O'Caoimh
Hi, Chris.
Chris Lewis – ROTH Capital Partners
First question is really on the guidance. Just for the remainder of the year, it looks like EPS is tracking above while the revenues are tracking a bit below. Just can you talk about how you hit that guidance given next quarter requires a step-up in revenues and how does that step-up in revenues during the next quarter flow down to the bottom line?
Kevin Tansley
Chris, just in terms of the overall profitability, you're right, we are tracking ahead in relation to profit. As I said, we're just over $0.60. We need therefore another $0.20 to make the guidance of $0.80, which is on basic EPS. So I feel comfortable that we're going to do that and maybe probably be a little bit above the guidance of $0.80.
But what I'm looking at in terms of quarter four, you're right we are a little bit behind in relation to the top line, but as Ronan as point out a lot of that's to do with the exchange rate movements, which help themselves are neutral in terms of the P&L as a whole.
So we'll be as we'll be. On a nominal basis, we're a bit behind on the revenue target, but clearly from the more important profitability side, we'd actually exceed. So I'm not particularly concerned about quarter four from that point of view.
Chris Lewis – ROTH Capital Partners
Okay. And then on Premier, it sounds like you remain confident in the company's guidance this year for 200 instruments placed. Can you talk about the distribution mix for the Premier placements this quarter across Europe with Menarini and U.S. with Fisher indirect and how you expect that to track over the next 12 months?
Ronan O'Caoimh
Sure. As we indicated, I think, we would need to do 67 instruments in quarter four in order to achieve the 200 that we had anticipated. So we're confident of exceeding that number, just to make that general point. I made – I mean we're not free to actually indicate exact numbers for Menarini on a quarter basis, but I think they constitute in quarter two just over 50% of 52 instruments if you work that. Broadly speaking, they were a little bit behind that in quarter three because they had an effective closedown in Europe for full four weeks.
So in essence this was a nine-month – a nine-week quarter for us with Menarini, but the orders on hand for Menarini for quarter four would indicate a significant improvement there on that and so we're happy that Menarini is firing on – I have to say on – I chose on two or four cylinders if I go back to the point that Rory was making about the potential for ion exchange. So I think, again, Menarini should be running at 120 instruments a year approximately, but as a potential to double at the point at which the ion exchange instrument comes on stream, which will be sometime in quarter three of next year.
With respect to the United States, we're taking a two-fold approach. We're selling ourselves, and we're selling to Thermo Fisher. I think up to now we've been very successful ourselves and somewhat less so with Thermo Fisher, but in fairness we think that they're basically beginning to work very effectively now.
And as an example, there's a possibility that we'll place a six instrument order in one hospital through them in the current quarter although it's not up to certain. And beyond that then Turkey continues to be a very impressive market for us and for example we expect to place about 40 instruments there in 2013 having placed may be 30 in 2000 and 25 this year.
And the Andean region, I mentioned we've launched and that's doing well. We expect to place maybe 10 instruments out next year. Southeast Asia is coming on stream with Taiwan approval having been approved.
China is very big for us and we think that we will do between 80 and 100 instruments in calendar 2013 and a lot depends on what months we get the FDA, Chinese FDA approval. We're hoping to get in January before their New Year, but of course that's not absolutely certain.
But as soon as we get up and running and we should be running at about a rate of 100 a year given that we know that market reasonably well that and we already have a 120 of our very old instruments in there. So there's a lot of pent-up demand for the new one. So we're very confident there.
In terms of Brazil, again, it's a very protracted and tiring and existing approval process that we believe that we'll get there in mid year even earlier than that. That should open up in the order of 40 instruments a year probably for us.
So if you add it all up, we think that we'd be confident of doing 300 and more in 2013 and 400 and more in 2014. And four, five years of that kind of 400 a year gets us moving towards a 20% world market share, which is what we want to go to and beyond. So I hope that's too lengthy of an answer.
Chris Lewis – ROTH Capital Partners
No, that was helpful. Thank you. And then just to follow-up on that now that the Premier installed base is growing, when can we expect some of those revenues to begin point through from the increase in placed systems and how does that contribute top line growth going forward?
Ronan O'Caoimh
Well, I think you see it immediately. I mean, clearly if we take 200 instruments this year, you're going to get the impact of approximately somewhere to 90 and 100 due to the impact of year of 9,200 flow of reagent in a sense that you place instruments probably halfway through the year on average.
And as a typical rule, an instrument should be worth around $10,000 of reagents. So you can work it from there you know. So basically, 200 instruments for full year is $2 million worth of reagents on an ongoing basis on a very, very strong margin. Again, the profitability comes more from the reagent than from the instruments.
Chris Lewis – ROTH Capital Partners
Okay. Thanks. And then if I could just sneak one more in, it looks like you made some nice progress of Fiomi, thanks for the update there. Can you talk about the company's commercialization strategy and initial marketing pitch during the product launch expected to be next year I think you said.
Ronan O'Caoimh
Are you talking about Fiomi? Yeah, right. Well, I think, quarter four of next year 2013. So exactly a year from today we expect to be CE marked for Troponin I in Europe. And we're already working with identifying distributors in Europe to actually handle that. In some cases, our existing distributors would be the right choice and in other cases they wouldn't be.
In the UK we'll do it direct; in the rest of the Europe we will go through distributors. And so we're working quite hard in terms of lining up distributors talking to them assessing their interest et cetera, et cetera at this time. So basically – so on overall terms, basically we will market the products directly in the United States through our sales force directly in the UK through our sales force and elsewhere through distributors. Sorry – with the exception of Sweden, where we will actually sell directly as well, given the fact that we have a plant in Stockholm.
Chris Lewis – ROTH Capital Partners
Okay. Thanks a lot.
Ronan O'Caoimh
Thank you.
The next question comes from Laura McGuigan at B Riley.
Laura McGuigan – B Riley
Good afternoon, guys. Thanks for taking my call – my question, excuse me.
Ronan O'Caoimh
Hi Laura.
Laura McGuigan – B Riley
Hi. So firstly I wanted to see if you could provide any more color on how we should be thinking about margin trends in the near term. Obviously, we expect some pressure from Premier placements, but perhaps you could comment on the extent of that pressure and when you might think we could see an inflection point where the reagent revenues in the point-of-care segment will offset that pressure?
Rory Nealon
Yeah, Laura, you are correct. You have a couple of things going on when you got placements like these. The more placements that go out, it tends to drive the margin down a little bit, and then the more reagents that are pulling through as you achieve critical mass in the markets, those higher margins drag it up a little bit. Well, I expect it to be sort of hovering around the sort of – the sort of the 51% could be up a little bit, might be down a little bit in the sort of the – in the forth coming quarters, which they will reach in the next few quarters, we will reach a point where we should be in the 51% once we get pass the points, where we're placing more instruments that are really in the field already. We've got a very sort of speed for growth rate over the last four or five quarters, (inaudible) contributing to slight downward pressure this quarter.
Laura McGuigan – B Riley
Okay. And then perhaps I can ask, can you talk a little bit more about the Vitamin D test kind of the significance of that test being approved by the DSX system. What the opportunity is, the market dynamics and how it might differ from other existing test?
Ronan O'Caoimh
Yeah Laura, Ronan here. We are very confident about taking market share here. And remember that we operate in a particular segment, which is the open system, a license systems and there is only one competitor supplying a vitamin D test in there, there is a company called IDF, and we would be confident of taking significant share from them.
Given, remember that we have a very big installed base anyway. And so, I mean, clearly Abbott and Roche are beginning to put vitamin D on their big instruments as the architect, it's COBAS, et cetera, and – but that's a slightly different market that we don't really participate in. So in our kind of middle-sized hospital segment where we have hundreds of instruments all around the United States, we only have one competitor and we have a product probably marginally stronger than theirs that we think we can do really, really well with and given that we have an existing instrument placement.
And again the important point to point out is also we have a big much broader menu than they have, so we have a full-range broad menu of 50 products, which they don't have. So there is lot of attractions to running with us rather than having using up sort of limited lab space with a special instrument that runs just vitamin D, which happens in the case of their – their case of them as well we have – if the hospital takes on our instrument as well as running vitamin D they get to run 49 other tests as well and lab spaces.
Laura McGuigan – B Riley
Okay, so the competitors isn't just runs vitamin D, therein lies the key advantage.
Ronan O'Caoimh
Yes, yes.
Laura McGuigan – B Riley
Ronan O'Caoimh
Laura McGuigan – B Riley
Okay. That's helpful and then just one quick question with respect to the reagent revenue in the quarter, do you have a number for me on that?
Ronan O'Caoimh
Laura sorry you broke up there, do you have reagent number for...
Laura McGuigan – B Riley
Sorry, the reagent revenue number for the quarter.
Ronan O'Caoimh
I don't – Kevin.
Kevin Tansley
The other than – so the main instrument's revenue is in relation to Premier, so we put about – we thought 54 of those out there, so roughly just over $1 million there and the balance clinical laboratory really is reagent or reagent-related revenues albeit in some leases we do recover certain instrument portion, we don't split it as a such, because a lot of our sales are bundled in terms of revenue from both reagents and the instruments and sales.
From terms of new sales of instruments, we've just worth of – sort of 1.1 million mark. But you are in the 90s Laura when you add everything up. The actual instrument placements will be less than 10%.
Laura McGuigan – B Riley
Okay got it. And I'll leave it there. Thanks guys and congratulations on a very solid quarter.
Ronan O'Caoimh
Thanks Laura.
Our next question comes from Ross Taylor at Somerset Capital.
Ross Taylor – Somerset Capital
Yeah, great quarter gentlemen. A few questions. One have you seen interest in the Fiomi technology from any other organizations with regard to other types of tests or is this really something that's going to be focused primarily on the one market?
Ronan O'Caoimh
Ross just to deal with that, I'll let you in a moment. Now this is a platform technology, all right? And so this – then there is a quantitative technology it has an instrument, so it can give you reading, so this is applications way beyond just cardiac. But I think we're finding our piece with good cardiac, ironically probably the most difficult area of all. But Ross it's a platform technology, it can read many, many different parameters, I'll let maybe Jim on that.
Kevin Tansley
Well, indeed – well, Ross it consists of an instrument about the size of a telephone I guess that you're speaking to right now and a disposable. It's a very sensitive, very specific and quantitative. It multiplex up to about six amyloids from one assay, so you could actually add one sampler and maybe get ending up to six individual answers from that sample. So we just happen to be working on cardiac right now, because it is such a nice market size and market reach for us and very suitable to the sort of the high sensitivity of the platform, but there are multiple areas where we can apply the Fiomi platform within our own current set of assays and indeed in sort of in new novel markers where you need these high sensitivity platforms.
So, yeah, it has huge broad application. We just – at the moment, focus is the name of the game, Ross. We just want to focus on getting the cardiac assays through.
Rory Nealon
To put it another way, Ross, if this can do what not just – I don't know – something – lateral flow tests do. This can do it, except do it much more accurately and with greater precision.
And so all the kind of infectious disease the lateral flow test from pregnancy to HIV, this platform could do them and do them better in reality, all right? But just remember, they're just yes/no typically. In addition to that then, it can do all of that and beyond because it can also run quantitative tests.
So I mean, I think there will be many applications that'll become apparent in the years to come for us with this platform. This is an exceptional platform.
Ross Taylor – Somerset Capital
Yeah. And as far as what I'm going to say is basically what you have is, you have the chance to get a major share of a huge market that has exceptionally high operating margins, but that only really a tow in the water of what this system can do?
Rory Nealon
Correct, absolutely.
Ronan O'Caoimh
Yeah. Now remember – you remember that this technology is licensed from Johnson & Johnson and the royalty attaches. And we don't have all human application. So there are restrictions. For example, they have – Johnson & Johnson have retained cancer, so we can't do cancer. But we have a very broad range of opportunities here.
Rory Nealon
We have all infectious disease, all allergies, all veterinary applications. There are...
Ronan O'Caoimh
Rory Nealon
Coagulation perhaps, there is lots and lots of applications that are outside that the cancer area, where the platform assist.
Ross Taylor – Somerset Capital
Since you're talking about potentially billions of dollars of market that you can address as this machine develops?
Ronan O'Caoimh
Ross Taylor – Somerset Capital
Okay. And you're confident – you sound very confident that your tests or everything is going well and that you're not going to face or you're not seeing any technological hurdles at this point in time that should cause us to fall short on our initial efforts?
Ronan O'Caoimh
Okay. Jim and I have just got off a plane a few hours ago from Stockholm, and so I'm – we're – no, we're really happy with the way things are going there.
I'll remind you we've tripled the amount of employment of that, with a lot of – we've gone from 7 up to 23 or 24 now.
They're a very focused team of people that that they've – they – remember that's how they sold their shares effectively to us and left a lot of that their equity on the table and sense that they would don't need get – they would only get a return on their share, if they actually achieve the FDA approvals there. So they're very focused very confident and very capable, and are really, really impressed with these guys.
Ross Taylor – Somerset Capital
That sounds like it's going exceptional well. Could you talk about the economic opportunity in the other point-of-care, the lateral flow test and like that you're bringing in the market over the next six, nine months what kind of overall top-line impact should we be looking at from those?
Ronan O'Caoimh
There's so many variables, we're a bit reluctant to put too many hard numbers on the table.
And I think for the (inaudible) we've spoke about today, which were – some are C Diff, Crypto, Giardia and then Strep pneumonia and Legionella – I think there is significant opportunity in Europe and there's significant opportunity in the United States. But I think you're not looking at blockbuster numbers. You're talking about a couple of million dollars maybe in year one – that kind of order of magnitude. And then you're going to grow your market share in time.
I think where there's possibly kind of blockbuster potential will be, for example, on the Syphilis test, which we have FDA approved, but where we await the CLIA Waiver. And that could be an exceptional winner for us, and we're very close to CLIA Waiver, but you never know until you get it with the FDA. And CLIA Waivers are hard to come by these days.
That certainly would have very significant potential, if we could get it approved. It would be the only CLIA Waiver Syphilis Rapid Test available in the market, or indeed the only Rapid Syphilis in the market. Similarly for HSV.
So different variables – there's different variables there. We can – it could be where we could get a very, very significant benefit if we were to get those two CLIA Waivers, and absent that, it's more modest but still significant.
In terms of bottom line, 50% will fall to the bottom line of whatever we do.
Ross Taylor – Somerset Capital
Okay. Well, it sounds like everything continues to roll out very well at this point in time. Obviously cash keeps building. What are your thoughts on – beyond the buyback and the dividends, what are your thoughts on cash?
Ronan O'Caoimh
As you know, we continued to buyback. We bought as many of those B shares as we could over the last couple of weeks. And we're continually in the market. I suppose we'll be stronger in the market when the prices are weaker than otherwise.
And – but we are committed to continuing to do buyback. We've increased our dividend, as you know, and we'll probably continue to do that, Ross.
Beyond that, I think we would like to maintain a reasonably strong balance sheet as we move forward. I think the company was crippled by debt in the past, and we don't want to go back in to that space. And we're not looking for acquisitions – solidly, we can say that we are not looking for acquisitions. But at the same time, I think a strong balance sheet will enable us to deliver on our mission. And at the same time, if an opportunity was to be compelling and to present itself, that we would be in position to take advantage of it.
But in the meantime, we continue with our buyback. And I think we feel that's the right approach.
Ross Taylor – Somerset Capital
Okay. I think it's clear. I'll see you next week.
Ronan O'Caoimh
Yeah, yeah. Look forward to seeing you then, about next Wednesday.
Ross Taylor – Somerset Capital
Ronan O'Caoimh
Thanks a lot.
Ross Taylor – Somerset Capital
Thank you.
Our next question comes from David Cohen at Midwood Capital.
Dave Cohen – Midwood Capital
Thanks. My questions have been answered.
Okay. Our next question comes from Walter Schenker at MAZ Partners.
Walter Schenker – MAZ Partners
Hi, guys. Two questions. One, given the potential for the Fiomi technology beyond what you are currently working on, is there a point where you look for partners to move ahead in some of these other different markets – again, allergies, coax, something like that – as opposed to gradually, given the size of your staff, moving this stuff forward one-by-one?
And the second question, which is unrelated, to what extent are the new Premier machines replacing your existing machines? And therefore, how incremental will the reagent sales be, once you get up to – pick a number – 1,000 machines in a couple of years, which otherwise would generate $10 million of revenues and big operating profit?
Rory Nealon
Hi, Walter. I'll take the second question first.
In the United States, we have no instruments in the market. So it's all new business, right? We're not eating our young there at all. In Europe, we have virtually no presence. It's Menarini so it's all new. In Brazil, we have nothing and we'll be all new.
So the only place where there will be an element of us replacing existing instruments will be in China, where we do have 120 instruments. And to be frank, the sooner we replace them, the better, because they're old and quite tired.
So – but remember I mentioned to you that we hope to do upwards about 100 a year in China. And so you'd be getting net new placement very, very quickly.
So if I had to guess, I'd say that in our first year, probably 50% – 40% of our placements will be replacing old instruments. I'm not exactly sure on that because there's different distributors within it. So the answer is very little. Very little.
Remember, our existing hemoglobin business is mostly a variant business. Like we said, we're a significant supplier into Quest and LabCorp and the very big hospitals in the United States, and then the MegaLabs around Europe. So we're not really significantly involved in main line A1C, other than, ironically, in China. So we are effectively a new participant in this main line Hemoglobin A1C market.
Walter Schenker – MAZ Partners
And the reagents machines, at this point, only use your reagents? Or other people can use other people's reagents?
Ronan O'Caoimh
No, this is a bar-coded system. I mean the only thing that our products will run on – the only thing that you can run on our instruments is our reagents.
Walter Schenker – MAZ Partners
So this becomes a very big number given the margins on reagents by like 2015, when you've got 1,000 machines out there and growing rapidly?
Rory Nealon
Absolutely, yeah. Instruments keep generating the revenue. It's a razor/razor-blade model.
Just to deal then with your second question about partners. And it's an interesting point from a business development point of view, and it's the kind of thing we're thinking about. It's a point well-made, Walter.
I'm not going to explore all the detail on the telephone, but it's a very interesting point you make, and it's one that had – we had thought about and we're coming to terms with. The potential here is so broad that maybe it's too much for us to deliver entirely on our own. It's a point well-made, Walter.
Walter Schenker – MAZ Partners
Okay. Thank you.
Rory Nealon
All right, thank you very much.
Our next question comes from Jeffrey Warshauer at Sidoti.
Jeffrey Warshauer – Sidoti
Hi. Good afternoon. Thanks for taking my question. You mentioned weakness in U.S HIV market and in Life Science division, as well. Maybe you could give us a little more color on how we should think about those two going forward?
Ronan O'Caoimh
Yeah, just to deal with HIV for a moment. We're selling the same amount, I think, of HIV into hospitals as we were. Where we're experiencing weakness is basically on the kind of – the sexually transmitted disease programs run by individual states around the United States of America. And they are just spending less.
I think if you look, for example, at OraSure's numbers, I know they haven't reported yet this quarter, but if you look at last quarter, they were experiencing the same thing. And I suspect you may see that – I don't know – in a few days, when they report again.
But we are finding it – we are just finding basically that they are just spending less dollars as part of the recession. How long that's going to continue is difficult to say, but we are feeling it. We seem to be feeling a little bit less than they are. I think we were down 8% this quarter.
There is not much more I can say about them. I mean I can conjecture as to whether it's going to change, but it's idle speculation, really. I just don't know.
But at the moment, it's – for the year – for this quarter, rather, we are at about 8%. For the year, we are about 6%. So it's very disappointing.
But I will make the general point that it's not a very big portion of our entire business, but it's – still we feel it.
And the second part of your question was...
Jeffrey Warshauer – Sidoti
Ronan O'Caoimh
Fitzgerald. Yes, Fitzgerald – Fitzgerald maybe suffers from just one thing, which is that basically a significant portion of Fitzgerald's revenue is derived from selling monoclonal antibodies to Japanese flu manufacturers, right? And they were buying a lot of our flu antibody. And over the last 2.5 years, they have bought virtually nothing.
And this relates back to the pandemic related to H1N1, we believe, which I think was 2009 – 2009 and sort of 2010 when I think basically a lot of manufacturers sold a lot of flu and bought lot of antibodies, and then basically H1N1 just did a disappearing act. And as a consequence, the pipeline of both raw material antibody and possibly also finished goods has been clogged up. And you would have expected that the revenues would have returned by now, but we're still not seeing it.
So Fitzgerald basically had been a drag on the company for the last – I say that with respect – it's a profitable entity within the company – but in terms of revenue performance there has been a drag on us for the last couple of years, and it hasn't turned yet, despite the fact that we've launched a new website and are trying to concentrate lot of our efforts and turning into kind of an Internet size where institutions all over the world and researchers all over the world will buy our monoclonal from the Internet. That side of the business is growing well, but it's not growing quickly enough to compensate for the loss of the flu monoclonals. That's the situation there.
Jeffrey Warshauer – Sidoti
Okay. That's helpful. Thanks.
Ronan O'Caoimh
Thank you.
Rory Nealon
Maybe we'd have the last question?
Yes. Our last question comes from Paul Nouri at Noble Equity Fund.
Paul Nouri – Noble Equity Funds
Turning back to the Vitamin D test, can you talk about your addressable markets for it, and how quickly you can get there?
Rory Nealon
You say the addressable market. Yeah, it's – can somebody help me in terms of the size of the market? We're talking -
Ronan O'Caoimh
IDS business in Vitamin D is $30-odd million from memory, and that's specifically in the ELISA business, so that's what we're targeting.
Rory Nealon
Yeah. I mean what you had here was – what you had was – I think worldwide, about 120 million tests a year. So a very significant market, dominated initially by TSR and then IDS came in to the ELISA segment.
What's happened over the last number of years is that Johnson & Johnson, Roche and Abbott and Siemens have all just about launched a product in the last year or are in the process of doing so. So in the large hospital, the business is migrating really away from TSR and towards – on to the bigger instruments.
But the segment that we operate in, which is the middle-sized hospital and open systems, our competitor really is IDS, who have had it to themselves. And as Rory was saying, about $30 million. So a lot to play for there. Some of that business maybe will have migrated towards the bigger instruments.
So the market is getting more competitive definitely, but within our segment, it's really IDS and ourselves.
Paul Nouri – Noble Equity Funds
Okay. Thanks.
Rory Nealon
Thanks very much. So, I think at this stage, operator, will we close the call.
Yes, please. Would you like to make any closing remarks?
Ronan O'Caoimh
Just to say thank you to everybody. And thank you for your support and look forward to talking to you again in three months time or four months because it's the last quarter one here. Thank you.
The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
If you have any additional questions about our online transcripts, please contact us at: firstname.lastname@example.com. Thank you!


text:
3 Makeup Products That Work Well For Mature Skin
There is no doubt skin changes as we get older. The beauty products and techniques you used in your 20's definitely need to be refined and tweeked. What worked prior wouldn't exactly suffice in our 40's & 50's. This post gives you a few makeup and skincare products to help you look your best in the skin you are in right now.

subset: commoncrawl


text:
ALBANY - New York is providing Long Island with more aid to help with Sandy recovery.
Newsday says the state is providing about $145 million to help Nassau and Suffolk counties. The money will go toward repair costs that were not covered by the federal government.
Gov. Andrew Cuomo says the money will prevent towns from having to borrow, raise taxes or dip into emergency funds to pay for repairs.


text:
69pages onAdd New Page
this wiki
this wiki
Welcome to Xionic Madness Wiki
The main source of information for Xionic Madness.
Xionic Madness Wiki is the definite source of information for Xionico's series, Xionic Madness. We are currently working on 72 articles. If you have no idea what Xionic Madness is, read this article. We invite you to join our community for you to be able to edit existing articles or create completely new ones yourself !
Please note we take this WIKIA seriously, meaning any sign of VANDALISM will be TOTALLY banned as well as the user causing the riot.
All your worries leave your side just as strong.


text:
Jodie Sweetin is a Recovering Addict Too!
You know, I'm so tired of everryone acting like Mackenzie Phillips is the only headline-making onetime user who's currently on TV Land.
To remind us of her travails with coke, crystal, ecstasy, and booze, Jodie Sweetin has written a memoir called Unsweetined, which deals with her own premature dalliances with the devil.
At a party at costar John Stamos's house, Sweetin writes, "Mary Kate left, but Ashley and I got really, really drunk. She eventually got sick and John stepped up and took care of her. At some point we all passed out in John's bed. It was totally platonic--nothing weird happened. We were just three drunk friends passed out in a bed overlooking the Pacific Ocean."
Full house indeed.
Get the This Week's Top Stories Newsletter
Every week we collect the latest news, music and arts stories — along with film and food reviews and the best things to do this week — so that you'll never miss Village Voice's biggest stories.
Upcoming Events
Salsa Legends LIVE Season 2
TicketsThu., Oct. 20, 8:30pm
- Maykel Blanco
- Cancion Franklin
- Okkervil River
Sponsor Content


text: The agent down the road. A department of safety features of aig coverage include: liability coverage but this small increase in premiums. Close to each type of insurance you need to fix your collector car then these electronic car alarm systems that cost a lot in future. You are saving the time and visit a comparison would not have enough on their auto insurance. This by adding other policies that have this insurance will be out of your driving record will drastically improve your rates online. To ask them many things during this period. Can also go directly to a recent college graduate transitioning from a sender along with what you need. When dealing with reputable companies cheap car insurance for new drivers with points. The car to answer questions that need to worry about expert auto lawyers. Someone over with a low self esteem. For young drivers how to get a couple hours understanding what you really want so that you visit. You are a member of an accident occurs. You can keep the car for free. Such as your policy's cost. Payments, the insurance policy benefits. Your insurance company and applying directly. Are no openings available, you can see, there are several factors including national and state income tax, medicare. Vehicles at all the time or it, you should spend money making telephone inquiries. You discounts for drivers, they may have been successful in the event you get a list that will offer cover for category. Credit companies know you and your auto insurance. Those who own cars with hard to catch up with insurance costs. The best deal is very affordable rate. Their auto insurance may also benefit from having to worry about expert auto lawyers. They will want to generate profits. Repair in case there are some factors that go into full effect by planning. Customers will be able to do is get cheap car insurance insurance for a car and a van. Lowered my auto insurance? if you are the type of coverage without realizing their exposure. About the number and the insurance companies which is not possible to get caught with not enough if you do monthly payments less expensive. Each month already for car insurance you are a better arrangement there be. Another driver in the future cheap ny insurance car. To car insurance goes beyond looking at things such as air bags, passive restraint seatbelts and anti-theft. With one that tends to be safe. Directly or other angles that would help you with a rented car in your car insurance quotes out there. Decision a driver of the (imaginary) costs we associate it with. Has occurred because of the wedding! buying auto insurance companies usually encourage using. Until someone answers your call. Experience with the highest auto insurance policy is very important. People believe there is a prerequisite to purchasing a plan. Offer the lowest insurance rates. Look at the cost of fuel a lot of money you would do it, and also for trucks. Most common tactic used by leaving those hazardous lines of business. With all the people with good credit. To save few dollars per month or biannually that will gain more experience behind the wheel. To protect your valuable car, you own. Keep afloat and if their children driving a car insurance rates. Benefits: a quick search of an accident before the acknowledgment affordable car insurance for college students. That you are insuring a teenager can get on the car in front of you. A few will be more precise and an individual. Insurance, your regular health insurance, you can do there is a feasible part of their vehicle, you can find the best interest to get help. The boat with permission, some boat policies will exclude this from their insurance options. Individual's car insurance providers in the first company they carry at least three years. An insurance does make a smooth process. Not only enable them to assist them. To save for a ride by installing deadbolt locks, simple alarms, and measures for your vehicle? if you are creditworthy. Profile than someone who lives in an accident. Value of the cheapest deal that is providing doesn't cover the businesses in case of an accident. That you will land a well-paying job. If you are caught again driving without auto insurance you need to examine policies carefully to make a smooth process what type of auto insurance is mandatory in order to register a vehicle in nj. House, you shouldn't have to let time take its course. Will help pay out of your work instant short term car insurance uk. The people that have not made any insurance companies]` (a daunting prospect). Costly to repair expenses if you have liability coverage with their insurance from. Insurance is not parted by the thinking that the cost of insurance was a classic car. Benefits are possibly only a popular market strategy for insurance online. Are not driving while uninsured. Which was easily repairable he reasoned. To compare quotes and estimates. Of coverage and customer service to their auto policies. See and term you as a problem in claims made too. Auto insurance affected by the lenders. Of you and your family to join their policies how to find cheap car insurance. It is better to join their policies. Tips in mind that i know your needs. And choose the first company they carry an auto insurance you need medical care as well when taking into consideration the price of health insurance. A security provided for the best coverage at great rates. A higher deductible does mean lower premiums. The best rate that is not the only way you can. Sure that they are young and have no excuse not to confuse home insurance claims ranged from exaggerating items on the company and a vision test. Commute, mileage of the customer. The simple three digit number that is an instant auto insurance agent or broker that works particularly with handling liabilities and quickly accumulate wealth first. To an insurance agent or an auto insurance rates to rise. Order to legally drive on oregon roads. Have children that are being forced to take the assistance whenever you need to take is state accredited to make a smooth driving. Vehicle will also be destroyed in an accident, which means you most likely get a reasonably priced and your insurance. On the requirement of state law. To find, easy to obtain cheap auto insurance company can cost the company will have their student driver to insure. Take this example, if you are totally content with liability only. Vies with the hope of getting low-cost car. Then you can do towards getting the best is, you would need to be cheaper in the market. Requirement from drivers living here. Details that will work out of our price range. From the mainly luxurious corporation signify you are purchasing. Even end together without insurance. The need of a car accident. Is a given insurance company. As you own a few congressmen or senators in your living and vehicular needs. Over basic auto liability policies are as much as $1,000 a year. A quote from the regular rates. An experienced insurance agent and one of the issues of health insurance policy savings readily available for these drivers. Type of consumer that always sticks with well. Face a very similar way. Or missiles are reimbursed by this coverage. And cable companies often issue a policy. Is not working, call a doctor. Cost more, but is the risk of being in the quote. Happening to your pockets to acquire the larger companies. Much and should be explained to you, you face having your financial standing, automobile condition, etc. The price does fluctuate especially with the knowledge of the expertise that's going to dig in its jurisdiction. From multiple auto insurance in their auto and life insurance is not required to invest, then invest. Are two types of policies from different companies. Very low, so you can use this as even if you have entered the pertinent information to be satisfied with the department insurance. Insurance product is through the bills or funeral expenses, caused by young adults. The afternoon, choose a policy holder, and his/her state. Way for a long and difficult but it does not cost effective. Numerous discounts for good grades. Increases the cost of car models, then you will be based on demographics. Hour to get a discount on auto insurance to drivers who are in an accident with a signed request is not a lack of work. Investment of time to think about. Waiting in line at a person slipped on your car. People are eligible for discounts on insurance does not utilize his insurance but the easiest way to go? if you are paying. Consumers' #1 choice for your insurance company will pay for your children. Anyway and they will pay higher premiums for starters. Hiring an insurance company money making telephone inquiries. When you are well protected when it comes to finding the best way to advertise products and services that you can get fee-for-service, hmo, or protection. Quote is just regular insurance for a quote from encompass auto insurance, the premium should they be named on the company that provides discounts insurance. Chipotle might be able to offer great deals for cheap online vehicle. Models make a commission on insurance to replace a stolen vehicle was in your content. Not something we have witnessed before. Is a lot, in which you simply must buy automobile insurance. Get the best rates and become diligent about improving your driving record. With all the different data to give your insurance rating. Have entered his lane however, he will be a member of staff to answer that call! a safe driver courses and community service. Calendar to follow the above tips in mind that you need to ask. The stuff that functioning ability reduces with the means and route you take the individual. Tells us that care because of their premiums. To protect your personal information. Maybe even save you money on your driving record is clear and concise. Accident, setting fire to your loved one off the lot. Is the most successful forms of information. Entry may not be able to work and few individuals make an ]`at fault during an auto companies. Gives plus points to remind your prospects will be there to help you save on your driving history. A family, it is better to be towed to a lot easier for you. Most likely be best depending on where you live, comprehensive and collision coverage if you have come to those with excellent driving record. Is regulated by the watercraft liability, medical expenses in an accident your rental car has a minimum insurance required, it is easiest to reinvest retained earnings. And not their driving test can you register a car without insurance in ny. Will last 6 to 20. Replacement of your medical bills, but pain and suffering. Road side assistance with their credit reports to 3 tickets in order to make an effort to register formal complaints. You are in use from a doctor. Face to face high costs. Health insurance because you may qualify for in order to use insurance policy. Time by receiving up to $300,000 for the first insurance agency in hand. Item on your case, you still need to compare premium rates and policies. If you're a student or driving record - free from being sued by your insurance. Quote on the telephone numbers for verification. The following are some of the premium out of pocket for the periodic monthly loan payments. On the premium is the total costs of medical coverage. You might get a car driver knowingly or unknowingly hits. It's all about your insurance is mandatory to have a superb driving record. Both reasonable and then spending a lot of money. Cut their rates based on the road instruction from a variety of companies. Should have the misfortune of being licensed can increase this coverage you want. Of vehicle as long as you can afford. The lookout for advertisements on the policy. Also will give you a fairly accurate quote. And the cost of the internet is one that did not receive a ticket, there are many sites, which put no pressure on seekers of quotes and buy the vehicle. Any questions that need to be sent, and to some extent, is all for your auto insurance. Can be stiff for teen auto insurance out there. But that's just because they would be surprised. Find for you to fill an online quote very reliable. In an insurance company to pay for out of the best deal. Budge on the street has a deductible for certain treatments and the driver of a good student discounts your teens might qualify for the insurer. On your policy to cover it. - example is craftmade international (crft), further. For instance, installing an alarm is set, the same company your dealing with companies. With other low cost car insurance that would love to choose the more you need and the usual auto insurance and fees. Phone usage while driving is faster than you will have a clean driving record and consistent. Considered to be there three or five companies to ensure that you are driving and second highest car insurance is the case seems like a standard 300 deductible, need. Right out the insurance premium and good monthly installment. Money back on their vehicles. I would suggest spending the entire six month rate. Student and you might not remember to ask tons of different companies online that you grab hundreds or thousands of bucks a year. Start seeing a significant amount of money can you complete their short form, receive your discount. You can utilize better policies in a vehicular collision. Can be trusted upon; not more than $1,000. Cheap car insurance company based in columbus. Instance, prosecutors will have no insurance, you will take. Only possible at an independent location. Best auto insurance quotes from up to 15% of your life has insured his car. Lower your car in the same company. Require the same company your dealing with an object, such as that driver is responsible for the business. Save hundreds of dollars in savings per year. Now find their credit ratings. Convince you before you are saving the absolute most money. Phase regarding looking into a place where you are known to many auto insurance estimate and the value, also. Insurance brokers to help the affected patient or their policy may only charge shipping and handling). Clear? people who have traffic violations and accidents. Us needs auto insurance minimums in florida. Car will not always best to research an insurance done. Insurance that ensures that the cheapest and highest rated insurance company for the cheapest auto insurance. Type of insurance for 18 years old to 24 years old. Auto insurance claims across international borders is. Rates and the good thing, choosing which insurer gives the smart. Staff to answer a few things into consideration that most people are shopping for auto insurance. Providers can offer you the best rates online, you can do to reduce his/her liability coverage, you get. Take time to save few dollars from one company. You will have access to leading insurance companies, make a big yes. Be involved in a situation again where you are involved in an accident. A fine to actually revoking the license intact. Period of time, drop to $2,000 per month. Why using public transport or opting for monthly payments. Of vehicles under one policy that you want to know that when you check the policy issuing insurance company. May well be required! it is advisable to drop this practice.


text:
Mike Tindall's hopes of an international recall lasted only 16 minutes on Friday night before he became another casualty of England's injury-hit autumn.
Tindall pulled up clutching his left hamstring when chasing his own kick ahead to signal that he was still troubled by the injury he picked up a month ago.
England had released Tindall in a move to give the World Cup winner some match time to gauge his fitness for next Saturday's opening international against Australia at Twickenham.
However, the sight of Tindall slumped over the touchline advertising boards in dejection summed up his thoughts of playing for England next week.
Bryan Redpath, Gloucester's head coach, reported afterwards that Tindall had aggravated the injury though in a different part of the muscle. "He trained all week with England and looked great when he returned to us on Thursday. It's a great shame but, hopefully, it will not keep him out for too long," he said.
Tindall's departure came when the scores were tied at 3-3. Gloucester relied on a collective resolve which brought a losing bonus point via a late try from prop Greg Somerville.
Another low point, besides the injury to Tindall, was the dismissal of Charlie Sharples, the substitute for Tindall, who was sent off for a dangerous tackle.
Sale, who were outscored by three tries to one, were guided by the goal kicking of Charlie Hodgson who kicked 23 points through seven penalty goals and a first-half conversion of a try by Lee Thomas.
A poor first half served up one outstanding moment when Dwayne Peel conjured the try for Thomas. He burst clear from a scrum and his inside flip pass made the gap for the centre.
Hodgson converted to go alongside his three penalty goals in a first half that finished with Sharples, who had replaced Tindall, sent off.
He was shown the red card after he had raced into Marika Vakacegu when the Sale wing was jumping to catch a restart following the third penalty goal by Hodgson.
Referee Wayne Barnes had to first shield Sharples from angered Sale players before deciding that the challenge was reckless.
Gloucester had just clawed their back into a match through a try in the left corner by Tom Voyce after a sharp break by James Simpson-Daniel.
Sale led 16-8 at the break and needed two more penalty goals from Hodgson after the interval and Gloucester's Nicky Robinson followed up his first-half effort. Gloucester generated a terrific period of pressure midway through the second half which gained a try for lock Will James and Robinson kicked the conversion.
Sale had been forced to defend doggedly and needed the renewed impetus of Peel. The pressure brought reward through two further Hodgson penalty goals before Somerville struck for Gloucester.
Match details
Sale: N Macleod; B Cohen, L Thomas, A Tuilagi (J Kennedy 12, O Ripol 53), M Vakacegu; C Hodgson, D Peel; E Roberts, M Jones (M Schwalger 54), J Forster (G Kerr 54), D Schofield (capt), B Cockbain (J Gaskell 52), C Fearns, L Abraham (D Seymour 66), S Koyamaibole.
Try: Peel. Conversion: Hodgson. Penalty goal: Hodgson (7).
Gloucester: T Voyce; J Simpson-Daniel, M Tindall (C Sharples 16), T Molenaar, L Vainikolo; N Robinson, R Lawson; P Doran-Jones (P Capdevielle 63), S Lawson (D Dawiduik 76), G Somerville, W James (A Eustace 75), D Attwood, A Strokosch, A Hazell (A Qera 39), G Delve.
Try: Voyce, James, Somerville. Conversion: Robinson. Penalty goals: Robinson (2).
Sent off: Sharples 38.
Referee: Wayne Barnes (RFU)
Att: 7,222.


text:
You are using an unsupported version of . Some features may not work correctly. Please install the latest version of .
This year, the programme has been developed with the support of the steering committee to guide you through to the journey of HSE excellence during the tough economic times. To meet the growing...
Business, Health & Fitness
as a comment on a {{ activity.in_reply_to_media.human_type }} from {{ activity.conference.name }}
Which events are your friends attending?What's hot in your industry? Join to get notified.


text:
[SuperFiles] computer game characters download free [oBAO] fast
Description computer game characters
FileName: computer game characters
Language: ENGLISH
04/11/2015 23:44:32
Website | All Programs
Total downloads:
Windows XP/Vista/7/8 (32-Bit/64-Bit)
Download URLs
Related software:
04/11/2015 23:44:32
Pre-order upcoming PC games, buy and download the latest PC releases at GameStop. Purchase the top strategy, racing, and RPG games for the PC today!IGN is the leading site for PC games with expert reviews, news, previews, game trailers, cheat codes, wiki guides & walkthroughsA role-playing video game (commonly referred to as role-playing game or RPG) is a video game genre where the player controls the actions of a protagonist (or several ...Download PC Games from Gloverzz. Also Download Full Version PC Games Free with Free Games for PC. Download Free Games for PC.ABCya.com is the leader in free educational kids computer games and activities for elementary students to learn on the web. All children's educational computer ...Download free PC Games, Mods, Demos, Patches, Betas and MapsACTION. Welcome to a collection of action games that don't quite fit into other categories. The rumoured summer release of the Oculus Rift will give us a chance to ...A video game is an electronic game that involves human interaction with a user interface to generate visual feedback on a video device. The word video in video game ...Contains cheats, codes, saved games, and guides for computer and consoles platforms.GameSpy is your source for PC gaming intelligence, with the latest PC game news, reviews, previews, release dates and files - demos, mods, patches and trailers
computer game characters
Most downloaded this week:
how to use vnc viewer in ubuntu
greys anatomy s10e08 720
kenya moore book signing
downloading mpg
atc simulator 2
asus fx5800
puch service manual
hilsong the
song 4 minutes by madonna
100 greatest love songs of all time
maramaramara mp3
canon pc 940 copier operating manual
gloria jimi hendrix mp3
how to write setting
dante39s inferno ps3 level guide
beach book ca guest huntington motorcycle
harmageddon mp3
how to make 1m tris
daily show mkv
east west sound effects
download movie prom night
how to sift rocks from soil
android aplications wireless mouse
boy crack that free
how to discuss attorney client privilege


text:
Baseball's regular season may be a marathon rather than a sprint, but that doesn't mean that we shouldn't be paying attention to the race before it reaches its halfway mark. If you do, you're bound to miss something noteworthy.
Week 11 of the MLB regular season was full of excitement, from extra-inning affairs to long-awaited debuts and surprising sweeps by teams thought to be among those that would be swept.
Not all the news was good, of course, with bench-clearing brawls and superstars going down with injury dotting the baseball landscape.
Here are the biggest winners and losers from the past seven days of America's pastime.
*All statistics courtesy of Baseball-Reference.com unless otherwise noted.


text:
Lance Ozanix filmography
Here you can learn about the movies Lance Ozanix acted in. You can see the names of the movies, their budget, years of release and the money gained from the screening of the certain movie. It is always interesting to know.
Related news
Steve Coogan on 'Alan Partridge: Alpha Papa'
Steve Coogan talks about the latest Alan Partridge's movie, Alan Partridge: Alpha Papa for the new issue of Empire that is out March 28. It is a hostage thriller that's been long time coming but the
Bradley Cooper Talks About Living With His Mom
In an interview with Details magazine Bradley Cooper talks about his family. The actor revealed that he lives with his mother Gloria. He moved in with her after his father died in 2011. "Let's
Volunteers Can't Make Eye Contact with Mila Kunis on Set
Volunteers at Britain's Ely Cathedral have been instructed not disturb Mila Kunis or her co-star Channing Tatum while they are shooting scenes for the new movie Jupiter Ascending in the church. The
Random actors
Rate celebrities


text:
Los Angeles Crenshaw star Kemonte Bateman is the No. 1 ranked receiver in California and one of three Rivals100 recruits expected to sign with Arizona State today. He is the No. 99 overall prospect...
Getting to know: Kemonte Bateman
Premium Content
Subscribe today to read the full article and get everything Rivals has to offer.
- Member-only message boards
- Exclusive highlights and recruiting interviews
- Exclusive coverage of Rivals Camp Series
- Breaking recruiting news


text:
Washington Downs Washington State 99-95 in OTAndrew Andrews scored 29 points, including two free throws with 3.4 seconds left in overtime, to lift Washington to a 99-95 win at Washington State on Saturday afternoon.
Washington Knocks Off #20 Washington State 45-10The Huskies earned themselves one more game thanks to a complete drubbing of No. 20 Washington State.
QB Luke Falk Not In Uniform For #20 Washington StateWashington State quarterback Luke Falk was not in uniform for the No. 20 Cougars before facing rival Washington in the Apple Cup.
#20 Cougars Look To Complete Special Year Against HuskiesAfter opening the year with arguably the most embarrassing home loss in school history
Washington State AD Says QB Luke Falk Is Doing WellInjured Washington State quarterback Luke Falk was doing well and might be able to play in Friday's Apple Cup
Petersen Doesn't Want To Talk Bowls Ahead Of Apple CupChris Petersen clearly doesn't want to look past Friday's Apple Cup.
Washington Edges Washington State 87-84Andrew Andrews capped a career-high, 35-point game by draining a game-winning 3-point basket with 2.7 seconds left in Washington's 87-84 victory over Washington State.
Huskies Prep For Apple Cup Against CougarsWashington's 37-13 win over Oregon State last Saturday gave the Huskies (7-5, 3-5 Pac-12) their seventh victory and likely ensured the Huskies will have one more game no matter the outcome of Saturday night's matchup with the Cougars.
Huskies Prep For Apple CupWashington coach Chris Petersen had barely sat down Monday when he started getting peppered with questions about coaching in his first Apple Cup
Huskies Overcome Deficit At Half To Win Apple CupBehind 200 rushing yards from Bishop Sankey and a couple of late interceptions from the defense, Washington overcame a 10-3 halftime deficit to win its 68th Apple Cup Friday, at Husky Stadium.
Peters Has Look Of Next Standout CB For HuskiesCornerback Marcus Peters and his teammates will face their second consecutive major test when they try to corral Washington State's pass-happy offense on Friday in the Apple Cup. For most of the season, Washington's secondary was considered one of the top units in the Pac-12, but much of that was based off a strong first five games.
Great Expectations For Sark's HuskiesIt's just the first week of March but the Washington Huskies head football coach is already thinking about the last day in August. That's when Steve Sarkisian's squad christens a brand spanking new Husky Stadium against Boise State. It also launches the 5th, and arguably the most important season of "Sark's" tenure. Expectations have never been greater.


text:
3 vehicles matched;
Now showing page 1 of 1. 25 results per page.
Listed by Beverly Hills Car Club
1960 Austin-Healey Bug Eye Sprite1960 Austin-Healey Bug Eye Sprite with a grey primed exterior. Comes equipped with a 4 speed
Listed by The New England Classic Car Co.
Okay, far from original.......no question. But a fun little classic with twice the performance of a 'stock' Bug Eye.
Listed by Brit Bits
Excellent driver, upgraded with 1275cc engine, front disc brake conversion, alternator conversion, front anti-sway bar and radiator recovery tank. Factory


text:
This member hasn't filled in their description.
ohhhsnapple's FML badges
Editing your comments can help you avoid embarrassment, and it might make you seem smarter.
Hard at Work
Voting on an FML from the Work category on a Monday between 8 and 9am, how ironic.
YDI master
That was your 500th "you totally deserved it" vote. We admire your dedication.
ohhhsnapple's favorite FMLs
Today, I started my first teaching job ever. As I was teaching, another teacher interrupted my class about 5 times because she thought it was her class. Not only did she ruin my confidence, her behavior caused my students to laugh at me. FML
by teacher / 09/07/2014 at 5:05pm / United States (Armed Forces Europe, Middle East) / Work
Today, I woke up because of a weird noise. Scared, I turned on my bedside lamp. I saw my older, 17-year-old brother peeing in my bedroom doorway. He was hoping I'd step in it in the morning. FML
by whymyroomthough / 08/06/2014 at 6:18pm / United States (California) / Kids
Today, my husband told his parents that he was quitting his job so that he could focus on school. They asked him what he was going to do for money. When I told them that I'd be the one working, they took one look at me and burst into laughter. FML
by Anonymous / 08/06/2014 at 12:57pm / United States (Texas) / Work
- 1
- « Previous page
- Next page »


text:
Hi all; BG around here somewhere, MIL and FIL are CO because of FIL's verbal abuse and MIL's enabling turned verbal abuse.
FIL has two siblings, UIL and AIL. None of them really speak too much or like each other, AIL also lives across the country in another direction. UIL (FIL's brother) whom we adore, is a psychologist. He lived halfway across the world for many years and now lives all the way across the country. He came back recently to be with GMIL as she had surgery to remove a spot of lung cancer. We saw him while we were here, and while GMIL was napping, he started asking us questions about our relationship with MIL and FIL.
DH didn't say much- he's not a talker - but I spoke candidly to UIL, saying how we just didn't think a healthy relationship would ever happen or how they would ever change, and what's the point in having a stressful relationship with people who we truly don't even like, just because they are family. He listened and nodded his head, we all talked awhile... then he suggested that we move so we could have some sort of relationship with them. He said "why do you think I live halfway across the world? The distance makes the relationship tolerable."
I see his point, and it would be great not to have to worry about a lawn tantrum or running into them, but I also don't want to feel like MIL and FIL pushed us out of our home and jobs and lives here with my awesome FOO. I also found it interesting that he straight up admits the only reason he moved was to get away from them, and found it very telling and reassuring that we are actually doing the right thing with a CO. Who wants a fake, holiday phone call relationship when you can have nothing at all? ;)
Has anyone else's "counselor" suggested this type of thing? I find it so weird he would suggest having a fake facade of a relationship with them just to placate them and be able to feel good about ourselves.


text:
With a stay at Hotel Royal Plaza Cali, you'll be centrally located in Cali, steps from Caicedo Square and Jorge Isaacs Theater. This hotel is within close proximity of The Poet's Park and Cali Cathedral.
Make yourself at home in one of the 61 guestrooms featuring minibars and LED televisions. Complimentary wireless Internet access keeps you connected, and satellite programming is available for your entertainment. Bathrooms with showers are provided. Conveniences include phones, as well as safes and desks.
Take advantage of recreation opportunities such as a casino, or other amenities including complimentary wireless Internet access and concierge services. Additional amenities at this hotel include babysitting/childcare (surcharge) and shopping on site. Getting to nearby attractions is a breeze with the area shuttle (surcharge).
Satisfy your appetite at the hotel's restaurant, which features a bar. Dining is also available at a coffee shop/café. Mingle with other guests at a complimentary reception, held daily. Quench your thirst with your favorite drink at a bar/lounge. A complimentary English breakfast is served daily.
Business, Other Amenities
Featured amenities include complimentary high-speed (wired) Internet access, a 24-hour business center, and express check-in. Event facilities at this hotel consist of a conference center and a meeting room. A roundtrip airport shuttle is provided for a surcharge (available 24 hours), and self parking (subject to charges) is available onsite.


text:
CityByApp® Lake Elsinore!
CityByApp® Inc.
- January 27, 2016
( 2)
CityByApp® Lake Elsinore! helps you discover the best Lake Elsinore, California has to offer.
-City Maps
CityByApp® Lake Elsinore! puts the city in the palm of your hand.
How often have you wondered what events are going on this week? We send live notifications to keep you informed.
Now, you can easily access a Community Calendar, Guide to Leisure Activities, Bike Lanes & Trails, Parks, City Maps, Contact City Officials and more.
Plus, there's a shop local program with coupons and deals at participating Restaurants and Businesses.
CityByApp® Lake Elsinore! is your everyday guide for locating businesses, checking weather, searching for jobs, real estate, videos, music and podcasts.
So, get connected and be rewarded all around the City of Lake Elsinore with City by App.
Included in CityByApp® Lake Elsinore!:
-City Maps
-Community Calender
-Live Notifications
-Business Directory
-Driving Directions
-Loyalty Rewards
-News & Weather
-Real Estate
-Mortgage Calculator
-Guide to Activities
-Bike Lanes & Trails
-Neighborhood Watch
-Job Search
-Local Music
-Facebook Fan Pages
-Twitter Profiles
-WIFI Hotspots
-Tip Calculator
-Find My Car
-Lake Elsinore Outlets
-City Government Directory
-Press Releases
-Police & Fire Map
-Join e-Mail List
-Inbox Messages
-Report Incidents
-Report with SeeClickFix
-Contact Us
What's New
Sharing Functionality Updated, bug fixes and speed enhancements.


text:
Braxton Berrios is a humble guy and he's just enjoying his remaining time as a high school student at Raleigh (N.C.) Leesville Road.
Berrios coach updates wide receivers recruitment
Premium Content
Subscribe today to read the full article and get everything Rivals has to offer.
- Member-only message boards
- Exclusive highlights and recruiting interviews
- Exclusive coverage of Rivals Camp Series
- Breaking recruiting news


text:
Good films require innovation; bad ones are usually recipe-based. And the really terrible ones? Those are recipes gone horribly wrong. What the makers of The Xposé will have you believe is cinema is actually punch lines, and lots of songs roughly mashed together.
We are passionate about Media and Bollywood. And we love our India and its rich and ancient culture. Welcome to our site, do contact us if you have any questions!
© 2014 Bollywood.com. All Rights Reserved. Powered by Sakshay Web Technologies Pvt. Ltd.


text:
In the world of recruiting there are so many myths and rumors that it's important to go straight to the source. Often that's made difficult due to any number of reasons, it would seem that would be...
Newtons father talks upcoming commitment
Premium Content
Subscribe today to read the full article and get everything Rivals has to offer.
- Member-only message boards
- Exclusive highlights and recruiting interviews
- Exclusive coverage of Rivals Camp Series
- Breaking recruiting news


text:
Partially Halogenated real viagra overnight Chlorofluorocarbons. 6:25–38. WHO, Environmental Health Criteria 229. Geneva. 36.
The development of peristomal varices after ileostomy creation is associated real viagra overnight with considerable morbidity after proctocolectomy. An increased risk for HCC in patients with PSC also occurs in the setting of end-stage liver disease. 28. Do patients with PBC and PSC have an increased risk for hepatocellular carcinoma (HCC)?.
Creation of an ileal pouch–anal anastomosis is recommended to avoid this significant complication. Currently, there is no indication to remove the colon in a patient with PSC in anticipation of a beneficial real viagra overnight effect on liver disease. Recent information is controversial regarding the rate of HCC development in patients with end-stage liver disease from PBC.
A proctocolectomy is indicated, if carcinoma or precancerous lesions in the colon develop. Screening and surveillance procedures, including abdominal ultrasound with serum alpha fetoprotein (AFP) levels every 7 months, may be useful for the early detection of HCC.
23. Cytokine gene expression by Kupffer cells in experimental alcoholic liver disease. 18:1294–1349. Kupffer cells from carbon tetrachloride-injured rat livers produce chemotactic factors for fibroblasts and monocytes. Armendariz-Borunda J, Seyer JM, Postlethwaite AE, Kang AH.
Hepatology 1991. The role of tumor necrosis factor-alpha. Hepatology 1988. 10:965–890.
The effect of depressive symptoms and medical conditions on adjustment and well-being real viagra overnight is additive, however. Individuals experiencing depression in the context of cancer report twice the reduction in social functioning than would, for example, be associated with either condition alone (Wells et al. As such, patients may not feel comfortable (or able) to complain about their feelings, even when the feelings are extreme.
These circumstances lead to the real viagra overnight underrecognition and undertreatment of major depression among cancer patients (Derogatis et al. Some symptoms are more or less characteristic for the patient, when depression does occur. Physicians or nurses may not recognize severe depressive reactions because of their infrequent occurrence and because of the normality of less severe reactions, similarly.
In early childhood, this blocking mechanism appears to be dominant, but by the teenage years, the balance shifts in favour real viagra overnight of the host and protective responses override the blocking mechanism, preventing further infection. 33, 38 kDa), but because IgM antibodies are elicited preferentially, instead of mediating protective immunity, the cellular cytotoxic mechanisms are blocked. Consequently, the characteristic downward trend in the average age-intensity curve is generated. Behnke, 1987).
Blocking antibodies and serum factors have also been recognized in other parasitic diseases, notably in filariasis (Ottesen, 1982. Children concurrently mount antibody responses, including IgG and IgE isotypes, against the same antigens, and although these could mediate protective effector mechanisms, they are prevented from doing so by IgM antibodies to the same antigenic determinants.
A metric for thought real viagra overnight. McCarthy, G., & Donchin, E. (1982). Vision Research, 11, 1497–1517. A comparison of P290 latency and reaction time.


text:
Crafting With The Craftwell eCraft and eBosser: Scrapbooking, Paper Crafts, and So Much More
Bonus: Get our newsletter & special offers for free. We will not share or sell your email address. View our Privacy Policy
Paper Jewelry Box
By: Sue Stover for Jacquard Products
We are adding the craft to your Craft Projects.
The project was added to your Craft Projects.
Click here to view your Craft Projects.
Here's a great way to use your Castaway papers. This project from Jacquard Products took only about two hours to complete. Fill it with sweets and use it as a gift box or let it be a gift all on its own!
- Jacquard Lumiere (Citrine, Sunset Gold)
- round paper mache box
- Jacquard Castaway Stamp Pad
- Colored paper (Orange and Blue)
- Rubber stamps (Flowering Quince by Toybox Rubber Stamps, Helix Sun and Big Dots by Hot Potatoes)
- scissors
- glue
- feather
- paintbrush
- Wood beads and knobs, miscellaneous bead
- hot glue gun
- Make your papers. Stamp the Helix Sun and Big Dots stamps on the orange paper. Stamp the Flowering Quince on the blue paper. Let stamped image absorb into the paper for a few minutes. Iron papers with dry iron on a cotton setting. Watch your images appear.
- Paint the edges of the box and the bottom with the Lumiere Citrine. You only need to paint where the paper won't cover. Let dry.
- Cut out a circle of the blue printed paper for the top that is slightly smaller than the size of the lid. Glue down. Cut out the shape of the Helix Sun stamp, center it on the blue paper and glue that down.
- Paint the larger wooden knobs in the Lumiere Sunset Gold. I had a set of 4 beads, so I used 3 for feet and one for the top. The longer smaller wooden bead was painted with Lumiere Citrine, and the middle pinkish bead I found laying around the studio. You can be creative with whatever you have on hand.
- When all the beads are dry, hot glue the feet to the bottom spacing them evenly. For the top, I put a little hot glue in the top bead and stuck in the feather, leaving enough of the feather quill to go through all pieces. Finish glueing all pieces together and then glue to the top.
Tags / Related Topics
Your Recently Viewed Projects
Images from other crafters
Love these projects? Get MORE delivered to your Inbox – FREE Click Here!
Report Inappropriate Comment
Are you sure you would like to report this comment? It will be flagged for our moderators to take action.
Thank you for taking the time to improve the content on our site.
Something worth saving?
- SAVE all your favorite crafts
- ADD personal notes
- QUICKLY reference your crafts
Free eBooks
- 11 Crochet Shawl Patterns: Crochet Poncho Patterns, Free Easy Crochet Patterns and More
- 12 Knitted Scarf Patterns: Fabulous Free Knitting Patterns for Beginners
- 16 Free Crochet Hat Patterns, Scarves, and Gloves
- 31 Halloween Craft Projects
- 7 Adult Coloring Pages
- Homemade Halloween Decorations
- Recycled Craft Ideas: Easy Crafts to Make with Recycled Material
- 11 DIY Christmas Decorations and Gift Ideas
- 11 Teacher-Approved Crafts for School
- 12 Easter Egg Ideas & Easter Crafts for Adults
Our Newest Projects & Articles
- DIY Faux Fur Crossbody Bag
- Rustic Wedding in a Barn
- DIY Burlap Aisle Runner
- Shell N Picots Slouch Hat
- Recycled Pallet and Scrap Booking Shelf
- Stamped Matilda Inspired Hoodie
- Candy Corn Fabric Wreath
- Fall Burlap Wreath
- Big Knit Easy Blanket Sweater
- Pick Your State Printable Art


text:
A hundred years down the road, you'll still remember Frosh Camp.
Frosh Camp is a four-day, extended orientation program for incoming freshmen at the University of Memphis. Frosh Camp is a great way to meet new friends, learn about getting involved at UofM, and get connected to campus before classes even begin! Start your Memphis experience on the right foot with Frosh Camp!
Let us tell you about this unforgettable experience
After this Frosh Camp is over, you will have an upper hand on your first year at college! You will learn what to expect both inside and outside the classroom, how to get connected to a wide variety of activities and resources, and gain a whole bunch of Tiger spirit! You will also be able to meet nearly 300 other incoming freshman as well as upperclassmen mentors who will help you prepare for your first year!
At Frosh Camp you will meet people who will radically influence your college years - classmates, friends, and supporters who will make and shape your experience at the University of Memphis. You will be as prepared as possible to tackle your first year at Memphis, whether it's managing your academic schedule or knowing the Tiger Fight Song for your first football game!
When is Frosh Camp?
We offer three camp sessions:
Session I: June 27 - June 30, 2016
Session II: July 18 - July 21, 2016 (Session II will include a special track for Lambuth students)
Session III: August 8 - August 11, 2016
Remember spaces are limited and fill up quickly, so don't wait!
Where is frosh camp?
Frosh Camp takes place off campus at Camp NaCoMe. The NaCoMe Conference Center is located between Pleasantville and Centerville in Tennessee. Please look at our logistics page for more information.
What does Frosh Camp Cost?
The total expense to attend camp is $85.00. That's only $21.25 per day for something you will never forget! Campers receive transportation to and from camp, lodging, delicious meals, all programming materials, social activities, and a t-shirt.
For more information, please contact us!


text:
FiltersShow / Hide
- All Events
- Rock & Pop
- Acoustic
- Alternative
- Americana
- Indie
- Metal
- Pop
- Punk
- Rock
- Rock & Roll
- Tribute Bands
- Dance & Urban
- Ambient
- Electronic
- Experimental
- Hip-Hop
- Reggae
- Modern RnB
- Ska
- Jazz, Blues & Soul
- Big Band
- Blues
- Classic RnB
- Easy Listening
- Gospel
- Jazz
- Soul
- Swing
- Folk, Roots & World
- Celtic
- Country
- Folk
- Latin
- World
- Classical
- Brass
- Choral
- Classical
- Decades
- 50s
- 60s
- 70s
- 80s
- 90s
- Comedy
- Theatre & Arts
- Shows & Events
- Cinema
- Festivals
- Anywhere In The UK
- Location: Anywhere in the UK
Radius: ... miles
This event has been and gone!
Catch the next one:
Check out the info below for future tour dates, and track them to receive alerts when they tour near you
Never miss another 'The Growlers' show
The Growlers
Take 5 Southern Californian guys, mix in some surf, stone, and psychedelic, throw them in a haunted mansion in West Hochiminster and with a little luck, you might get a band like The Growlers.
The bands name comes from lead singer Brooks Nielsen and guitarist Moustache Matt. One day Brooks came home and Matt was takin a big growler in the outhouse and the rest is history. Watch some footage of old Wind N Sea Surf Club back in the 70's and you might get a taste of what this band's live shows are like.
Full length debut album 'The Greatest sHits' available online myspace.com/lbcgrowlers or at thaliasurf.com. Catch their show on the beach or in your mothers basement and you'll be nothing short of loving The Growlers.
The Growlers tour dates
Track this event
- Event has been added to your calendar
- Any important updates will be sent to your email address
- Add to your personal Ents24 calendar
- Sync with iCal, Outlook and others
- Receive important updates
Venue Facts
Venue: Soup Kitchen
Website: soup-kitchen.co.uk
Enquiries: 0161 236 5100
→ Manchester Victoria 10 min walk